Good Lifestyle

The recent surge In cases of COVID, hospitalizations and deaths have the country on Edge. Even the entirely vaccinated people are concerned, withRevolutionary infections to be reported and the disease control and prevention centers (CDC) reverse theirGUIDANCE WITHOUT MASK For vaccinated individuals. Although the experts maintain that vaccination is always the best way to protect yourself from COVID - especially serious illnesses, seeks that vaccines become less effective over time. In fact, the CEO of Pfizer has just revealed that the effectiveness of Pfizer begins to fall asearly also two months After people get their second dose.

RELATED:40% of people who get serious Covid after Pfizer has this in common.

During an episode of CNBC of July 29The exchangePfizer CEOAlbert Bourla discussed the conclusions of a newStudy funded by the company, which has not yet been examined by peers but has been published early as pre-expression on Medrxiv. Researchers have evaluated the effectiveness of vaccination for more than 44,000 Pfizer recipients in the United States and other countries over six months.

According to the study, the vaccine was the most protective between one week and two months after receipt of the second dose, with an efficiency of 96.2% against infection. But researchers also found that every two months, the efficiency of the vaccine declines approximately 6%. Between two and less than four months, the Pfizer vaccine fell to 90.1%.

The effectiveness of Pfizer after "four to six months was around 84%," Bourla said. Although it is slightly less protective against symptomatic infection, these results show that the vaccine is always very effective after four months. And in terms of serious illness protection, the Pfizer vaccine did not waver, staying at about 97%.

When asked if it was normal that the effectiveness of a vaccine falls so that after only four to six months, Bourla assured that "is not rare." However, he said that the study confirms the need for a third dose, adding that research has been completed before the Delta variant.

RELATED:For more information up to date, sign up for our daily newsletter.

"The good news is that we are very, very confident that a third dose, a booster, will take the immune response at the levels that will suffice to protect against the variant of Delta," he said. According to Bourla, Pfizer plans to officially submit data to US regulators on the benefits of a third dose of Covid vaccine by mid-August.

However, when Pfizer has announced for the first time his plans to push callbacks so soon, American regulators were not on board. On July 8, the Food and Drug Administration (FDA) and the CDC published a joint statementAgainst the thrust of Pfizer, insisting so that "Americans who have been completely vaccinated do not need a booster at that time."

By the declaration, the FDA, the CDC and the health institutes (NIH) (NIH) are currently involved in a "scientific and rigorous" process to determine whether, and when, a reminder vaccine may be necessary. "This process takes into account laboratory data, clinical trial data and cohort data, which may include data from specific pharmaceutical companies, but does not rely on these data exclusively," said agencies .

Other health experts have not been concerned about recall shots, in particular, in particular, given that many countries have not yet received sufficient vaccine doses to supply the first or second shots. "There is not enough evidence right now to support that it's one way or anotherOptimal use of resources, "Natalie Dean, PhD, a biostatistician at Emory University in Atlanta, saidThe New York Times.

RELATED:Pfizer only works against the delta variant if you do that, a new study indicates.